ID   MTREX_HUMAN             Reviewed;        1042 AA.
AC   P42285; Q2M386; Q6MZZ8; Q6P170; Q8N5R0; Q8TAG2;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2005, sequence version 3.
DT   07-APR-2021, entry version 214.
DE   RecName: Full=Exosome RNA helicase MTR4 {ECO:0000305};
DE            EC=3.6.4.13 {ECO:0000269|PubMed:29844170};
DE   AltName: Full=ATP-dependent RNA helicase DOB1 {ECO:0000303|PubMed:16782053};
DE   AltName: Full=ATP-dependent RNA helicase SKIV2L2;
DE   AltName: Full=Superkiller viralicidic activity 2-like 2;
DE   AltName: Full=TRAMP-like complex helicase;
GN   Name=MTREX {ECO:0000312|HGNC:HGNC:18734};
GN   Synonyms=DOB1 {ECO:0000303|PubMed:16782053}, KIAA0052,
GN   MTR4 {ECO:0000303|PubMed:26456651}, SKIV2L2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Myelomonocyte;
RX   PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S., Seki N.,
RA   Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II. The
RT   coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of
RT   cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [2]
RP   SEQUENCE REVISION TO C-TERMINUS.
RA   Ohara O., Nagase T., Kikuno R., Nomura N.;
RL   Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND INTERACTION WITH NVL.
RC   TISSUE=Kidney;
RX   PubMed=16782053; DOI=10.1016/j.bbrc.2006.06.017;
RA   Nagahama M., Yamazoe T., Hara Y., Tani K., Tsuji A., Tagaya M.;
RT   "The AAA-ATPase NVL2 is a component of pre-ribosomal particles that
RT   interacts with the DExD/H-box RNA helicase DOB1.";
RL   Biochem. Biophys. Res. Commun. 346:1075-1082(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Hippocampus, Natural killer cell, Prostate, and Retina;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-24; 82-98; 135-145; 185-192; 340-351; 385-396;
RP   409-418; 438-449; 451-464; 495-502; 533-542; 554-604; 681-701; 724-743;
RP   844-852; 861-873; 924-933; 985-995 AND 1013-1022, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Ovarian carcinoma;
RA   Bienvenut W.V., Lilla S., von Kriegsheim A., Lempens A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [7]
RP   ASSOCIATION WITH THE RNA EXOSOME COMPLEX, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=11719186; DOI=10.1016/s0092-8674(01)00578-5;
RA   Chen C.-Y., Gherzi R., Ong S.-E., Chan E.L., Raijmakers R., Pruijn G.J.M.,
RA   Stoecklin G., Moroni C., Mann M., Karin M.;
RT   "AU binding proteins recruit the exosome to degrade ARE-containing mRNAs.";
RL   Cell 107:451-464(2001).
RN   [8]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12429849; DOI=10.1091/mbc.e02-05-0271;
RA   Scherl A., Coute Y., Deon C., Calle A., Kindbeiter K., Sanchez J.-C.,
RA   Greco A., Hochstrasser D.F., Diaz J.-J.;
RT   "Functional proteomic analysis of human nucleolus.";
RL   Mol. Biol. Cell 13:4100-4109(2002).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE SPLICEOSOMAL
RP   C COMPLEX.
RX   PubMed=11991638; DOI=10.1017/s1355838202021088;
RA   Jurica M.S., Licklider L.J., Gygi S.P., Grigorieff N., Moore M.J.;
RT   "Purification and characterization of native spliceosomes suitable for
RT   three-dimensional structural analysis.";
RL   RNA 8:426-439(2002).
RN   [10]
RP   INTERACTION WITH ZCCHC8.
RX   PubMed=16263084; DOI=10.1016/j.bbrc.2005.10.090;
RA   Gustafson M.P., Welcker M., Hwang H.C., Clurman B.E.;
RT   "Zcchc8 is a glycogen synthase kinase-3 substrate that interacts with RNA-
RT   binding proteins.";
RL   Biochem. Biophys. Res. Commun. 338:1359-1367(2005).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH MPHOSPH6.
RX   PubMed=17412707; DOI=10.1093/nar/gkm082;
RA   Schilders G., van Dijk E., Pruijn G.J.M.;
RT   "C1D and hMtr4p associate with the human exosome subunit PM/Scl-100 and are
RT   involved in pre-rRNA processing.";
RL   Nucleic Acids Res. 35:2564-2572(2007).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-51, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   IDENTIFICATION IN A TRAMP-LIKE COMPLEX, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=21855801; DOI=10.1016/j.molcel.2011.06.028;
RA   Lubas M., Christensen M.S., Kristiansen M.S., Domanski M., Falkenby L.G.,
RA   Lykke-Andersen S., Andersen J.S., Dziembowski A., Jensen T.H.;
RT   "Interaction profiling identifies the human nuclear exosome targeting
RT   complex.";
RL   Mol. Cell 43:624-637(2011).
RN   [16]
RP   REVIEW ON RNA EXOSOMES.
RX   PubMed=22817747; DOI=10.1042/bst20120061;
RA   Sloan K.E., Schneider C., Watkins N.J.;
RT   "Comparison of the yeast and human nuclear exosome complexes.";
RL   Biochem. Soc. Trans. 40:850-855(2012).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-40, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   INTERACTION WITH THE RNA EXOSOME COMPLEX, AND INTERACTION WITH EXOSC10.
RX   PubMed=26166824; DOI=10.1016/j.bbrc.2015.07.032;
RA   Yoshikatsu Y., Ishida Y., Sudo H., Yuasa K., Tsuji A., Nagahama M.;
RT   "NVL2, a nucleolar AAA-ATPase, is associated with the nuclear exosome and
RT   is involved in pre-rRNA processing.";
RL   Biochem. Biophys. Res. Commun. 464:780-786(2015).
RN   [20]
RP   INTERACTION WITH WDR74.
RX   PubMed=26456651; DOI=10.1016/j.bbrc.2015.09.160;
RA   Hiraishi N., Ishida Y., Nagahama M.;
RT   "AAA-ATPase NVL2 acts on MTR4-exosome complex to dissociate the nucleolar
RT   protein WDR74.";
RL   Biochem. Biophys. Res. Commun. 467:534-540(2015).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-684, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [22]
RP   SUBUNIT, INTERACTION WITH ZFC3H1; ZCCHC8 AND RBM7, AND FUNCTION.
RX   PubMed=27871484; DOI=10.1016/j.molcel.2016.09.025;
RA   Meola N., Domanski M., Karadoulama E., Chen Y., Gentil C., Pultz D.,
RA   Vitting-Seerup K., Lykke-Andersen S., Andersen J.S., Sandelin A.,
RA   Jensen T.H.;
RT   "Identification of a nuclear exosome decay pathway for processed
RT   transcripts.";
RL   Mol. Cell 64:520-533(2016).
RN   [23]
RP   SUBUNIT, AND INTERACTION WITH ZCCHC8.
RX   PubMed=27905398; DOI=10.1038/ncomms13573;
RA   Falk S., Finogenova K., Melko M., Benda C., Lykke-Andersen S., Jensen T.H.,
RA   Conti E.;
RT   "Structure of the RBM7-ZCCHC8 core of the NEXT complex reveals connections
RT   to splicing factors.";
RL   Nat. Commun. 7:13573-13573(2016).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-24; LYS-358; LYS-684 AND LYS-723,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH WDR74.
RX   PubMed=29107693; DOI=10.1016/j.bbrc.2017.10.148;
RA   Hiraishi N., Ishida Y.I., Sudo H., Nagahama M.;
RT   "WDR74 participates in an early cleavage of the pre-rRNA processing pathway
RT   in cooperation with the nucleolar AAA-ATPase NVL2.";
RL   Biochem. Biophys. Res. Commun. 495:116-123(2018).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH NRDE2.
RX   PubMed=29902117; DOI=10.1080/15476286.2018.1467180;
RA   Richard P., Ogami K., Chen Y., Feng S., Moresco J.J., Yates J.R. III,
RA   Manley J.L.;
RT   "NRDE-2, the human homolog of fission yeast Nrl1, prevents DNA damage
RT   accumulation in human cells.";
RL   RNA Biol. 15:868-876(2018).
RN   [27]
RP   INTERACTION WITH NRDE2.
RX   PubMed=30538148; DOI=10.1261/rna.069773.118;
RA   Jiao A.L., Perales R., Umbreit N.T., Haswell J.R., Piper M.E., Adams B.D.,
RA   Pellman D., Kennedy S., Slack F.J.;
RT   "Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing
RT   factor.";
RL   RNA 25:352-363(2019).
RN   [28] {ECO:0007744|PDB:6D6Q, ECO:0007744|PDB:6D6R}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.45 ANGSTROMS) IN COMPLEX WITH NUCLEAR
RP   RNA EXOSOME COMPLEX AND DNA/RNA HETERODUPLEX, CATALYTIC ACTIVITY, FUNCTION,
RP   AND ACTIVITY REGULATION.
RX   PubMed=29906447; DOI=10.1016/j.cell.2018.05.041;
RA   Weick E.M., Puno M.R., Januszyk K., Zinder J.C., DiMattia M.A., Lima C.D.;
RT   "Helicase-Dependent RNA Decay Illuminated by a Cryo-EM Structure of a Human
RT   Nuclear RNA Exosome-MTR4 Complex.";
RL   Cell 173:1663-1677.e21(2018).
RN   [29] {ECO:0007744|PDB:6C90}
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 71-600 AND 843-1042 IN COMPLEX
RP   WITH ZCCHC8 AND ATP, INTERACTION WITH ZCCHC8, CATALYTIC ACTIVITY, FUNCTION,
RP   MUTAGENESIS OF GLU-253, ATP BINDING, AND ACTIVITY REGULATION.
RX   PubMed=29844170; DOI=10.1073/pnas.1803530115;
RA   Puno M.R., Lima C.D.;
RT   "Structural basis for MTR4-ZCCHC8 interactions that stimulate the MTR4
RT   helicase in the nuclear exosome-targeting complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:E5506-E5515(2018).
RN   [30] {ECO:0007744|PDB:6IEG, ECO:0007744|PDB:6IEH}
RP   X-RAY CRYSTALLOGRAPHY (2.89 ANGSTROMS) OF 71-1042 IN COMPLEX WITH NRDE2,
RP   INTERACTION WITH NCBP1; NRDE2; SRRT; ZFC3H1, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF ARG-658; GLU-697; ARG-743 AND 989-PHE-GLU-990.
RX   PubMed=30842217; DOI=10.1101/gad.322602.118;
RA   Wang J., Chen J., Wu G., Zhang H., Du X., Chen S., Zhang L., Wang K.,
RA   Fan J., Gao S., Wu X., Zhang S., Kuai B., Zhao P., Chi B., Wang L., Li G.,
RA   Wong C.C.L., Zhou Y., Li J., Yun C., Cheng H.;
RT   "NRDE2 negatively regulates exosome functions by inhibiting MTR4
RT   recruitment and exosome interaction.";
RL   Genes Dev. 33:536-549(2019).
RN   [31] {ECO:0007744|PDB:6RO1}
RP   X-RAY CRYSTALLOGRAPHY (3.07 ANGSTROMS) OF 70-1042 IN COMPLEXES WITH NVL AND
RP   ATP, INTERACTION WITH NVL AND ZCCHC8, ATP BINDING, AND MUTAGENESIS OF
RP   ARG-743.
RX   PubMed=31358741; DOI=10.1038/s41467-019-11339-x;
RA   Lingaraju M., Johnsen D., Schlundt A., Langer L.M., Basquin J., Sattler M.,
RA   Heick Jensen T., Falk S., Conti E.;
RT   "The MTR4 helicase recruits nuclear adaptors of the human RNA exosome using
RT   distinct arch-interacting motifs.";
RL   Nat. Commun. 10:3393-3393(2019).
CC   -!- FUNCTION: Catalyzes the ATP-dependent unwinding of RNA duplexes with a
CC       single-stranded 3' RNA extension (PubMed:27871484, PubMed:29844170,
CC       PubMed:29906447). Central subunit of many protein complexes, namely
CC       TRAMP-like, nuclear exosome targeting (NEXT) and poly(A) tail exosome
CC       targeting (PAXT) (PubMed:27871484, PubMed:29844170, PubMed:21855801).
CC       NEXT functions as an RNA exosome cofactor that directs a subset of non-
CC       coding short-lived RNAs for exosomal degradation. NEXT is involved in
CC       surveillance and turnover of aberrant transcripts and non-coding RNAs
CC       (PubMed:27871484, PubMed:29844170). PAXT directs a subset of long and
CC       polyadenylated poly(A) RNAs for exosomal degradation. The RNA exosome
CC       is fundamental for the degradation of RNA in eukaryotic nuclei.
CC       Substrate targeting is facilitated by its cofactor ZCCHC8, which links
CC       to RNA-binding protein adapters (PubMed:27871484). Associated with the
CC       RNA exosome complex and involved in the 3'-processing of the 7S pre-RNA
CC       to the mature 5.8S rRNA (PubMed:17412707, PubMed:29107693). May be
CC       involved in pre-mRNA splicing. In the context of NEXT complex can also
CC       in vitro unwind DNA:RNA heteroduplexes with a 3' poly (A) RNA tracking
CC       strand (PubMed:29844170). Can promote unwinding and degradation of
CC       structured RNA substrates when associated with the nuclear exosome and
CC       its cofactors. Can displace a DNA strand while translocating on RNA to
CC       ultimately degrade the RNA within a DNA/RNA heteroduplex
CC       (PubMed:29906447). Plays a role in DNA damage response
CC       (PubMed:29902117). {ECO:0000269|PubMed:17412707,
CC       ECO:0000269|PubMed:21855801, ECO:0000269|PubMed:27871484,
CC       ECO:0000269|PubMed:29107693, ECO:0000269|PubMed:29844170,
CC       ECO:0000269|PubMed:29902117, ECO:0000269|PubMed:29906447}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC         Evidence={ECO:0000269|PubMed:29844170, ECO:0000269|PubMed:29906447};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13066;
CC         Evidence={ECO:0000269|PubMed:29844170};
CC   -!- ACTIVITY REGULATION: Activated when MTREX is incorporated into NEXT
CC       complex an the nuclear RNA exosome complex.
CC       {ECO:0000269|PubMed:29844170, ECO:0000269|PubMed:29906447}.
CC   -!- SUBUNIT: Component of a TRAMP-like complex, an ATP-dependent exosome
CC       regulatory complex consisting of a helicase (MTREX), an oligadenylate
CC       polymerase (TENT4B or TENT4A), and a substrate specific RNA-binding
CC       factor (ZCCHC7 or ZCCHC8). Several TRAMP-like complexes exist with
CC       specific compositions and are associated with nuclear, or nucleolar RNA
CC       exosomes (PubMed:21855801). Identified in the spliceosome C complex.
CC       Component of the poly(A) tail exosome targeting (PAXT) complex made of
CC       PABPN1, ZFC3H1 and MTREX that directs a subset of long and
CC       polyadenylated poly(A) RNAs for exosomal degradation (PubMed:27871484).
CC       Component of the nuclear exosome targeting (NEXT) complex composed of
CC       MTREX, ZCCHC8, and RBM7 that directs a subset of non-coding short-lived
CC       RNAs for exosomal degradation (PubMed:27905398, PubMed:27871484).
CC       Interacts with ZCCHC8; this interaction bridges the interaction between
CC       RBM7 and MTREX (PubMed:27905398, PubMed:16263084, PubMed:29844170,
CC       PubMed:31358741). Binds to ZFC3H1 and RBM7 in a RNase-insensitive
CC       manner (PubMed:27871484). Interacts with EXOSC10; the interaction
CC       mediates the association of MTREX with nuclear RNA exosomes
CC       (PubMed:26166824). Interacts with isoform 1 of NVL in an ATP-dependent
CC       manner; the interaction is required to associate NVL with nuclear RNA
CC       exosome (PubMed:16782053, PubMed:26166824, PubMed:11991638,
CC       PubMed:16263084, PubMed:21855801, PubMed:27871484, PubMed:27905398,
CC       PubMed:31358741). Interacts with WDR74; the interaction dissociation in
CC       a late stage of rRNA synthesis is required for appropriate maturation
CC       of pre-60S particles and depends on the ATPase activity of NVL
CC       (PubMed:26456651, PubMed:29107693). Interacts with MPHOSPH6
CC       (PubMed:17412707). Interacts with the RNA cap-binding complex proteins
CC       NCBP1 and SRRT (PubMed:30842217). Interacts with NRDE2; the interaction
CC       is direct and negatively regulates MTREX function in exosomal
CC       degradation by changing its conformation precluding interaction with
CC       ZFC3H1, the RNA cap-binding complex proteins NCBP1 and SRRT, and
CC       association with the exosome (PubMed:30842217, PubMed:30538148,
CC       PubMed:29902117). Interacts with the nuclear RNA exosome complex
CC       (PubMed:29906447). {ECO:0000269|PubMed:11991638,
CC       ECO:0000269|PubMed:16263084, ECO:0000269|PubMed:16782053,
CC       ECO:0000269|PubMed:17412707, ECO:0000269|PubMed:21855801,
CC       ECO:0000269|PubMed:26166824, ECO:0000269|PubMed:26456651,
CC       ECO:0000269|PubMed:27871484, ECO:0000269|PubMed:27905398,
CC       ECO:0000269|PubMed:29107693, ECO:0000269|PubMed:29844170,
CC       ECO:0000269|PubMed:29902117, ECO:0000269|PubMed:29906447,
CC       ECO:0000269|PubMed:30538148, ECO:0000269|PubMed:30842217,
CC       ECO:0000269|PubMed:31358741}.
CC   -!- INTERACTION:
CC       P42285; Q99547: MPHOSPH6; NbExp=2; IntAct=EBI-347612, EBI-373187;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:30842217}. Nucleus, nucleolus
CC       {ECO:0000269|PubMed:12429849}. Nucleus {ECO:0000269|PubMed:16782053}.
CC       Nucleus speckle {ECO:0000269|PubMed:30842217}.
CC   -!- SIMILARITY: Belongs to the helicase family. SKI2 subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH65258.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA06124.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D29641; BAA06124.2; ALT_INIT; mRNA.
DR   EMBL; BX640789; CAE45877.1; -; mRNA.
DR   EMBL; BC014669; AAH14669.2; -; mRNA.
DR   EMBL; BC028604; AAH28604.3; -; mRNA.
DR   EMBL; BC031779; AAH31779.1; -; mRNA.
DR   EMBL; BC065258; AAH65258.1; ALT_INIT; mRNA.
DR   EMBL; BC104996; AAI04997.1; -; mRNA.
DR   EMBL; BC113509; AAI13510.1; -; mRNA.
DR   CCDS; CCDS3967.1; -.
DR   RefSeq; NP_056175.3; NM_015360.4.
DR   PDB; 6C90; X-ray; 2.20 A; A=71-600, A=843-1042.
DR   PDB; 6D6Q; EM; 3.45 A; M=1-1042.
DR   PDB; 6D6R; EM; 3.45 A; M=1-1042.
DR   PDB; 6IEG; X-ray; 3.55 A; A/B=71-1042.
DR   PDB; 6IEH; X-ray; 2.89 A; B=71-1042.
DR   PDB; 6RO1; X-ray; 3.07 A; A=70-1042.
DR   PDBsum; 6C90; -.
DR   PDBsum; 6D6Q; -.
DR   PDBsum; 6D6R; -.
DR   PDBsum; 6IEG; -.
DR   PDBsum; 6IEH; -.
DR   PDBsum; 6RO1; -.
DR   SMR; P42285; -.
DR   BioGRID; 117064; 156.
DR   CORUM; P42285; -.
DR   ELM; P42285; -.
DR   IntAct; P42285; 66.
DR   MINT; P42285; -.
DR   STRING; 9606.ENSP00000230640; -.
DR   ChEMBL; CHEMBL4105889; -.
DR   iPTMnet; P42285; -.
DR   MetOSite; P42285; -.
DR   PhosphoSitePlus; P42285; -.
DR   SwissPalm; P42285; -.
DR   BioMuta; SKIV2L2; -.
DR   DMDM; 71153172; -.
DR   SWISS-2DPAGE; P42285; -.
DR   EPD; P42285; -.
DR   jPOST; P42285; -.
DR   MassIVE; P42285; -.
DR   MaxQB; P42285; -.
DR   PaxDb; P42285; -.
DR   PeptideAtlas; P42285; -.
DR   PRIDE; P42285; -.
DR   ProteomicsDB; 55503; -.
DR   Antibodypedia; 23424; 215 antibodies.
DR   DNASU; 23517; -.
DR   Ensembl; ENST00000230640; ENSP00000230640; ENSG00000039123.
DR   GeneID; 23517; -.
DR   KEGG; hsa:23517; -.
DR   UCSC; uc003jpy.5; human.
DR   CTD; 23517; -.
DR   DisGeNET; 23517; -.
DR   GeneCards; MTREX; -.
DR   HGNC; HGNC:18734; MTREX.
DR   HPA; ENSG00000039123; Low tissue specificity.
DR   MIM; 618122; gene.
DR   neXtProt; NX_P42285; -.
DR   OpenTargets; ENSG00000039123; -.
DR   PharmGKB; PA134901921; -.
DR   VEuPathDB; HostDB:ENSG00000039123.15; -.
DR   eggNOG; KOG0948; Eukaryota.
DR   GeneTree; ENSGT00940000156183; -.
DR   HOGENOM; CLU_002902_0_1_1; -.
DR   InParanoid; P42285; -.
DR   OMA; CFVCDEK; -.
DR   OrthoDB; 176060at2759; -.
DR   PhylomeDB; P42285; -.
DR   TreeFam; TF300597; -.
DR   PathwayCommons; P42285; -.
DR   Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol.
DR   Reactome; R-HSA-72163; mRNA Splicing - Major Pathway.
DR   BioGRID-ORCS; 23517; 757 hits in 994 CRISPR screens.
DR   ChiTaRS; SKIV2L2; human.
DR   GeneWiki; SKIV2L2; -.
DR   GenomeRNAi; 23517; -.
DR   Pharos; P42285; Tbio.
DR   PRO; PR:P42285; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P42285; protein.
DR   Bgee; ENSG00000039123; Expressed in calcaneal tendon and 245 other tissues.
DR   ExpressionAtlas; P42285; baseline and differential.
DR   Genevisible; P42285; HS.
DR   GO; GO:0071013; C:catalytic step 2 spliceosome; IDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0031499; C:TRAMP complex; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0003724; F:RNA helicase activity; IDA:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:0000460; P:maturation of 5.8S rRNA; IMP:UniProtKB.
DR   GO; GO:0000398; P:mRNA splicing, via spliceosome; TAS:Reactome.
DR   GO; GO:0006401; P:RNA catabolic process; IDA:UniProtKB.
DR   GO; GO:0006364; P:rRNA processing; IMP:UniProtKB.
DR   GO; GO:0016076; P:snRNA catabolic process; ISS:UniProtKB.
DR   InterPro; IPR011545; DEAD/DEAH_box_helicase_dom.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR025696; rRNA_proc-arch_dom.
DR   InterPro; IPR016438; Ski2-like.
DR   InterPro; IPR012961; Ski2_C.
DR   Pfam; PF00270; DEAD; 1.
DR   Pfam; PF08148; DSHCT; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   Pfam; PF13234; rRNA_proc-arch; 1.
DR   PIRSF; PIRSF005198; Antiviral_helicase_SKI2; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM01142; DSHCT; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Direct protein sequencing;
KW   DNA damage; Helicase; Hydrolase; Isopeptide bond; mRNA processing;
KW   mRNA splicing; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; rRNA processing; Spliceosome; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.6, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22223895"
FT   CHAIN           2..1042
FT                   /note="Exosome RNA helicase MTR4"
FT                   /id="PRO_0000102094"
FT   DOMAIN          148..304
FT                   /note="Helicase ATP-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   DOMAIN          405..577
FT                   /note="Helicase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00542"
FT   NP_BIND         161..168
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   MOTIF           252..255
FT                   /note="DEIH box"
FT   BINDING         139
FT                   /note="ATP; via carbonyl oxygen"
FT                   /evidence="ECO:0000269|PubMed:31358741,
FT                   ECO:0007744|PDB:6RO1"
FT   BINDING         164
FT                   /note="ATP; via amide nitrogen"
FT                   /evidence="ECO:0000269|PubMed:29844170,
FT                   ECO:0000269|PubMed:31358741, ECO:0007744|PDB:6C90,
FT                   ECO:0007744|PDB:6RO1"
FT   BINDING         166
FT                   /note="ATP; via amide nitrogen"
FT                   /evidence="ECO:0000269|PubMed:29844170,
FT                   ECO:0000269|PubMed:31358741, ECO:0007744|PDB:6C90,
FT                   ECO:0007744|PDB:6RO1"
FT   BINDING         167
FT                   /note="ATP; via amide nitrogen"
FT                   /evidence="ECO:0000269|PubMed:29844170,
FT                   ECO:0000269|PubMed:31358741, ECO:0007744|PDB:6C90,
FT                   ECO:0007744|PDB:6RO1"
FT   BINDING         168
FT                   /note="ATP"
FT                   /evidence="ECO:0000269|PubMed:29844170,
FT                   ECO:0000269|PubMed:31358741, ECO:0007744|PDB:6C90,
FT                   ECO:0007744|PDB:6RO1"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|Ref.6, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22223895"
FT   MOD_RES         40
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         51
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         78
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9CZU3"
FT   CROSSLNK        24
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        358
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        684
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        723
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VARIANT         346
FT                   /note="A -> P (in dbSNP:rs35643285)"
FT                   /id="VAR_049343"
FT   MUTAGEN         253
FT                   /note="E->Q: Abolishes RNA helicase activity."
FT                   /evidence="ECO:0000269|PubMed:29844170"
FT   MUTAGEN         658
FT                   /note="R->A: Decreased interaction with NRDE2."
FT                   /evidence="ECO:0000269|PubMed:30842217"
FT   MUTAGEN         697
FT                   /note="E->R: Decreased interaction with NRDE2."
FT                   /evidence="ECO:0000269|PubMed:30842217"
FT   MUTAGEN         743
FT                   /note="R->E: Decreased interaction with NRDE2. Impairs the
FT                   binding of both NVL and NOP53."
FT                   /evidence="ECO:0000269|PubMed:30842217,
FT                   ECO:0000269|PubMed:31358741"
FT   MUTAGEN         989..990
FT                   /note="FE->AK: Loss of interaction with NRDE2."
FT                   /evidence="ECO:0000269|PubMed:30842217"
FT   CONFLICT        342
FT                   /note="N -> K (in Ref. 5; AAH14669)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        722
FT                   /note="E -> G (in Ref. 4; CAE45877)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        900
FT                   /note="L -> I (in Ref. 5; AAH28604)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        927
FT                   /note="Q -> R (in Ref. 4; CAE45877)"
FT                   /evidence="ECO:0000305"
FT   STRAND          99..104
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          107..109
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          111..117
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           142..152
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          156..160
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           168..180
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          184..191
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           192..206
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          209..212
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          223..228
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           229..237
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           241..243
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          246..251
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           254..256
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   TURN            257..261
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           263..272
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          278..284
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           289..300
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          304..308
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          316..322
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          329..332
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           340..348
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   TURN            355..357
FT                   /evidence="ECO:0007744|PDB:6RO1"
FT   HELIX           371..383
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          388..392
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           396..405
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           406..408
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           414..428
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           433..436
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           439..449
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          452..455
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          457..459
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   HELIX           461..472
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          477..481
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           483..487
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          488..490
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          493..499
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          501..504
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          509..511
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           514..521
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   TURN            527..529
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          531..539
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           545..553
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           567..575
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          576..578
FT                   /evidence="ECO:0007744|PDB:6RO1"
FT   HELIX           581..587
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           589..597
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           598..604
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   HELIX           608..614
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   HELIX           623..644
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   HELIX           647..650
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   HELIX           651..653
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   STRAND          658..664
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   STRAND          667..680
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   STRAND          693..702
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   HELIX           704..707
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   STRAND          720..722
FT                   /evidence="ECO:0007744|PDB:6RO1"
FT   STRAND          725..732
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   HELIX           733..735
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   STRAND          736..743
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   HELIX           753..769
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   TURN            779..782
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   HELIX           788..806
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   HELIX           808..811
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   STRAND          812..814
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   HELIX           815..840
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   TURN            841..843
FT                   /evidence="ECO:0007744|PDB:6IEH"
FT   HELIX           848..860
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          863..865
FT                   /evidence="ECO:0007744|PDB:6D6Q"
FT   TURN            866..868
FT                   /evidence="ECO:0007744|PDB:6D6Q"
FT   HELIX           872..877
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           885..894
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   TURN            895..899
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           902..909
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           910..912
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           926..948
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           955..960
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           967..974
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           979..983
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   STRAND          986..988
FT                   /evidence="ECO:0007744|PDB:6D6Q"
FT   HELIX           990..1013
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           1017..1030
FT                   /evidence="ECO:0007744|PDB:6C90"
FT   HELIX           1033..1036
FT                   /evidence="ECO:0007744|PDB:6C90"
SQ   SEQUENCE   1042 AA;  117805 MW;  49F47BEC753FBEE7 CRC64;
     MADAFGDELF SVFEGDSTTA AGTKKDKEKD KGKWKGPPGS ADKAGKRFDG KLQSESTNNG
     KNKRDVDFEG TDEPIFGKKP RIEESITEDL SLADLMPRVK VQSVETVEGC THEVALPAEE
     DYLPLKPRVG KAAKEYPFIL DAFQREAIQC VDNNQSVLVS AHTSAGKTVC AEYAIALALR
     EKQRVIFTSP IKALSNQKYR EMYEEFQDVG LMTGDVTINP TASCLVMTTE ILRSMLYRGS
     EVMREVAWVI FDEIHYMRDS ERGVVWEETI ILLPDNVHYV FLSATIPNAR QFAEWICHLH
     KQPCHVIYTD YRPTPLQHYI FPAGGDGLHL VVDENGDFRE DNFNTAMQVL RDAGDLAKGD
     QKGRKGGTKG PSNVFKIVKM IMERNFQPVI IFSFSKKDCE AYALQMTKLD FNTDEEKKMV
     EEVFSNAIDC LSDEDKKLPQ VEHVLPLLKR GIGIHHGGLL PILKETIEIL FSEGLIKALF
     ATETFAMGIN MPARTVLFTN ARKFDGKDFR WISSGEYIQM SGRAGRRGMD DRGIVILMVD
     EKMSPTIGKQ LLKGSADPLN SAFHLTYNMV LNLLRVEEIN PEYMLEKSFY QFQHYRAIPG
     VVEKVKNSEE QYNKIVIPNE ESVVIYYKIR QQLAKLGKEI EEYIHKPKYC LPFLQPGRLV
     KVKNEGDDFG WGVVVNFSKK SNVKPNSGEL DPLYVVEVLL RCSKESLKNS ATEAAKPAKP
     DEKGEMQVVP VLVHLLSAIS SVRLYIPKDL RPVDNRQSVL KSIQEVQKRF PDGIPLLDPI
     DDMGIQDQGL KKVIQKVEAF EHRMYSHPLH NDPNLETVYT LCEKKAQIAI DIKSAKRELK
     KARTVLQMDE LKCRKRVLRR LGFATSSDVI EMKGRVACEI SSADELLLTE MMFNGLFNDL
     SAEQATALLS CFVFQENSSE MPKLTEQLAG PLRQMQECAK RIAKVSAEAK LEIDEETYLS
     SFKPHLMDVV YTWATGATFA HICKMTDVFE GSIIRCMRRL EELLRQMCQA AKAIGNTELE
     NKFAEGITKI KRDIVFAASL YL
//
